Download PDF
Thromb Haemost 1996; 76(02): 280-281
DOI: 10.1055/s-0038-1650572
Letters to the Editor
Schattauer GmbH Stuttgart

Factor VIII Inhibitor and Severity of Hemophilia

Axel Schoppmann
Immuno AG, Vienna, Austria; Immuno Inc., Rochester, USA
,
A Thomas Waytes
Immuno AG, Vienna, Austria; Immuno Inc., Rochester, USA
› Author Affiliations
Further Information

Publication History

Received 13 March 1996

Accepted after resubmission 26 April 1996

Publication Date:
10 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints
 

  • References

  • 1 Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-John-son M, Shapiro A, Scheibel E, White III G, Lee M. Recombinate Study Group. A multicenter study of recombinant factor VIII (Recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. Blood 1994; 83 (09) 2428-2435
    PubMedSearch in Google Scholar
  • 2 Hoyer LW. Why do so many haemophilia A patients develop an inhibitor?. Brit J Haematol 1995; 90: 498-501
    CrossrefPubMedSearch in Google Scholar
  • 3 Lusher JM. Human antibodies to recombinant factor VIII in hemophiliacs. J Interferon Res 1994; 14: 173-174
    CrossrefPubMedSearch in Google Scholar
  • 4 Briët E, Rosendaal FR, Kreuz W, Rasi V, Peerlinck K, Vermylen J, Ljung R, Rocina A, Addiego J, Lorenzo JI, Pabinger I. High titer inhibitors in severe haemophilia A. A meta-analysis based on eight long-term follow-up studies concerning inhibitors associated with crude or intermediate purity factor VIII products (Letter to the Editor). Thromb Haemost 1994; 72: 162-164
    Thieme ConnectPubMedSearch in Google Scholar
  • 5 De Biasi R, Rocino A, Papa ML, Salerno E, Mastrullo L, De Blasi D. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates. Thromb Haemost 1994; 71 (05) 544-547
    Thieme ConnectPubMedSearch in Google Scholar
  • 6 Scharrer I, Neutzling O. Incidence of inhibitors in haemophiliacs. A review of the literature. Blood Coagulation and Fibrinolysis 1993; 4: 753-758
    CrossrefPubMedSearch in Google Scholar
  • 7 Green D, Di Michele DM. Hemophilia: factor VIII deficiency. In: Thrombosis and Hemorrhage Loscalzo J, Schafer AI. eds. Blackwell Scientific Publications; 683-687
  • 8 Aledort LM, Haschmeyer RH, Pettersson H. the Orthopaedic Outcome Study Group. A longitudinal study of orthopaedic outcome for severe factor-VUI-deficient haemophiliacs. J Internal Med 1994; 236: 391-399
    CrossrefPubMedSearch in Google Scholar
  • 9 Nilsson IM, Bemtorp E, Ljung R, Löfqvist T, Pettersson H. Prophylactic treatment of severe hemophilia A and B can prevent joint disability. Sem Hematol 1994; 31 (02) (Suppl. 02) 5-9
    PubMedSearch in Google Scholar
  • 10 Walker I, Pai M, Akabutu J, Ritchie B, Growe G, Poon M-C, Card R, Ali K, Israels S, Teitel J, Garvey B, Blanchette V, Giles A, Lillicrap D, Drouin J, Luke B, Gill K, Herst J, Lépine-Martin M, Inwood M, Rivard G, Strawczynski H, Jobin F, Demers C, Jardine L, Whitman L, Ingram L, Robinson S, Rubin S, Scully M-F, Dolan S, Ross E. The Canadian Hemophilia Registry as the basis for a national system for monitoring the use of factor concentrates. Transfusion 1995; 35: 548-551
    CrossrefPubMedSearch in Google Scholar
  • 11 Brettler DB, Levine PH. Clinical manifestations and therapy of inherited coagulation factor deficiencies. In: Hemostasis and Thrombosis Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ, Salzman EW. eds. J.B. Lippincott Company; Philadelphia, PA: 1994: 169-183
  • 12 Berntorp E, Boulyjenkov V, Brettler D, Chandy M, Jones P, Lee C, Lusher J, Mannucci P, Peake I, Rickard K, Seremetis S. Modem treatment of haemophilia. Bulletin of the WHO 1995; 73 (05) 691-701
    PubMedSearch in Google Scholar
  • 13 Gill JC. Therapy of factor VIII deficiency. Semin Thromb Haemost 1993; 19 (01) 1-12
    Thieme ConnectPubMedSearch in Google Scholar
  • 14 Amano K, Arai M, Koshihara K, Suzuki T, Kagawa K, Nishida Y, Fukutake K. Autoantibody to factor VIII that has less reactivity to factor VUI/von Willebrand factor complex. Amer J Hematol 1995; 49: 310-317
    CrossrefPubMedSearch in Google Scholar
  • 15 Rock G, Adamkiewitz T, Blanchette V, Poon A, Sparling C. Acquired von Willebrand factor deficiency during high dose infusion of recombinant factor VIII. Blood 1995 86. Abstract 760
    PubMedSearch in Google Scholar
  • 16 Vermylen J, Peerlinck K. Epidemic of factor VIII inhibitors linked to factor VIII-P (letter). Acta Clin Belg 1991; 46: 419
    CrossrefPubMedSearch in Google Scholar
  • 17 Paul-Ehrlich-Institut press release of Sept. 7, 1995. Paul-Ehrlich-Institut zieht Gerinnungspraparat zurück (Paul-Ehrlich Institute withdraws coagulation product)
    PubMed
  • 18 Yee TT, Williams MD, Hill FGH, Lee CA, Pasi KJ. Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to only a single intermediate purity factor VIII product. Blood 1995 86. Abstract 759
    PubMedSearch in Google Scholar
  • 19 Schimpf K, Schwarz H-P, Kunschak M. Zero Incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex. Thromb Haemost 1995; 73 (03) 553-555
    Thieme ConnectPubMedSearch in Google Scholar